Formulation and evaluation of in situ gelling system of dimenhydrinate for nasal administration

Pharmaceutical Development and Technology

Volumn 14, Issue 3, 2009, Pages 240-248

  Belgamwar, Veena S ^a   Chauk, Dheeraj S ^a   Mahajan, Hitendra S ^a   Jain, Snehal A ^a   Gattani, Surendra G ^a   Surana, Sanjay J ^a  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Dimenhydrinate; In situ gel; Ionic gelation; Mucoadhesion; Nasal drug delivery

Indexed keywords

CARBOMER; DIMENHYDRINATE; GELLAN; GEL; HISTAMINE H1 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; DRUG STABILITY; EX VIVO STUDY; GEL; GELATION; HISTOPATHOLOGY; MUCOADHESION; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; STRENGTH; VISCOSITY; ANIMAL; CHEMISTRY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NOSE CAVITY; PATHOLOGY; SHEEP;

ADMINISTRATION, INTRANASAL; ANIMALS; DIMENHYDRINATE; DRUG DELIVERY SYSTEMS; GELS; HISTAMINE H1 ANTAGONISTS; NASAL CAVITY; SHEEP; VISCOSITY;

EID: 70350654530     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802498910     Document Type: Article

References (12)

1. Money KE, Lackner JR, Cheung RSK. Te autonomic nervous system and motion sickness. In: Yates BJ, Miller AD, eds. Vestibular Autonomic Regulation. Boca Raton, FL: CRC Press; 1996:147-173.
2. Matsunaga T, Kubo T. Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol. 1993;501(Suppl):10-15.
3. Drug Facts and Comparisons. Pocket Version, 18th ed. St. Louis, MO: 2004;866.
4. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Controlled Rel. 2003;87:187-198. (Pubitemid 36255456)
5. Jiang X, Cao S, Chen E, Zhang Q. Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efcacy. Acta Pharmacol Sinica. 2007;28(4):584-590.
6. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the Gelrite® gellan gum-based ocular delivery system for indomethacin. Acta Pharm. 2003;53:251-261.
7. Watts PJ, Illum L. Pectin compositions for improved delivery of drugs to mucosal membranes. 2002; US Patent: 6,432,440.
8. Yong CS, Choi JS, Rhee JD, et al. Efect of sodium chloride on the gelation, gel strength, and bioadhesive force of poloxamer gels. Int J Pharm. 2001;275:195-205.
9. Murthy RSR, Majithiya RJ, Ghosh PK, et al. Termoreversible-mucoadhesive gel for nasal delivery of Sumatriptan. AAPS. Pharm Sci Tech. 2006;7(3):E1-7.
10. Zaki NM, Awada GA, Mortadaa ND, et al. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm. Sci. 2007;32:296-307.
11. Behl CR, Harper NJ, Pei JY, et al. A general method of accessing skin permeation enhancement mechanisms and optimization. In: Hsies DS, ed. Drug Permeation Enhancement: Teory and Applications. 1st ed. New York, NY: Marcel Dekker Inc.; 1994:115.
12. Jiang X, Cao S, Chen E, Zhang Q. A novel nasal delivery system of a chinese traditional medicine, radix bupleuri, based on the concept of ion- activated in situ gel. Arch Pharm Res. 2007;30(8):1014-1019.